The NA Vaccine Institute announced on the 20th that its glioblastoma treatment vaccine development project was selected for this year's first national new drug development project of the National New Drug Development Foundation.

Through this project, NA Vaccine Institute will receive support for the non-clinical development of a glioblastoma treatment candidate using a next-generation peptide vaccine platform for two years.

Glioblastoma (GBM) is a malignant brain tumor with an average survival time of 15 months, a 5-year survival rate of 3%, and a mortality rate of 95%. The standard treatment is temozolomide and radiation therapy after surgery, but the effect is not great. Although much research and development has been conducted on glioblastoma treatments for decades, there is still no clear alternative.

The NA Vaccine Institute is developing a glioblastoma treatment vaccine using its own next-generation peptide vaccine platform. Through this project, the goal is to enter phase 1 clinical trials for glioblastoma treatment within two years after completing non-clinical trials.

The peptide vaccine platform developed by the NA Vaccine Research Institute has dramatically improved vaccine effectiveness by utilizing Nexavant, a new immune adjuvant, and the NA Vaccine Research Institute's peptide platform technology.

The company evaluated that it can be easily applied not only to cancer but also to various infectious diseases, so it will be able to quickly respond to new infectious diseases. A company official said, "In the mid to long term, we will be able to improve and replace existing vaccine systems and increase our influence in the global pharmaceutical market through the development of various treatments."

Reporter Lee Ji-hyeon bluesky@hankyung.com